77
Views
0
CrossRef citations to date
0
Altmetric
Review

Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors

, , , &
Pages 521-526 | Published online: 24 Dec 2022

Abstract

In the last years there has been increasing evidence suggesting that the treatment of cardiovascular risk factors must be done on a global rather than on a separate approach, because they have additive effects and share common pathways leading to atherothrombosis. Of special interest is the relationship between hypertension and dyslipidemia. An excessive activity of the renin-angiotensin system (RAS), that plays an important role in hypertension, contributes to endothelial dysfunction, vascular inflammation and thrombosis. Dyslipidemia induces the same effects through similar mechanisms. In fact, combined therapy with statins and RAS modulators shows synergic beneficial effects in the treatment of atherosclerosis. Then, in the future, the traditional hypertension and dyslipidemia units should probably evolve into global cardiovascular risk management Units. Also, polypills combining antihypertensive and lipid-lowering drugs will make easier the treatment of these conditions. These changes would provide us the necessary tools to treat our patients in accordance with the current strategies of cardiovascular therapy and prevention.

Many years ago, the Framingham study and other studies began to identify a number of different risk factors as potential causes of atherothrombotic events (CitationKannel et al 1961; CitationMcGill 1996). Treating these risk factors emerged then as a capital task in the fight against cardiovascular disease. However, this approach has evolved notoriously in the last years. In the initial era, cardiovascular risk factors (CRF) were assessed and treated separately, but later, the avalaible information has shown us that this work has to be done based on a global approach. Clinical studies have demonstrated that CRF act in a synergistic way. In addition, we have learned from pathophysiological studies that there are mechanistic links between the pathways through which different CRF cause atherothrombosis. In this regard, of special interest is the relationship between the pathophysiology of hypertension and dyslipidemia.We will focus on the clinical and pathophysiological data relating to the development of these two factors, to support the concept of a global management of the patient with CRF.

Combined antihypertensive and lipid lowering therapies in the clinical practice

A large number of clinical trials has demonstrated that treatment of either hypercholesterolemia or hypertension leads to a reduction in the incidence of cardiovascular events. Also, statins and angiotensin converting enzyme (ACE) inhibitors demonstrated an additive effect reducing the incidence of cardiovascular events (CitationYusuf et al 2000; CitationHeart Protection Study Collaborative Group 2002).

The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) studies have shed new light into this matter. The ASCOT-BPLA (Blood Pressure Lowering Arm) analyzed 19,257 patients with hypertension and at least three other cardiovascular risk factors, which were randomized to therapy with amlodipine, adding perindopril when necessary, or to atenolol, using bendroflumethiazide as a second drug (CitationDahlof et al 2005). By the end of the trial, 78% of patients were taking the second antihypertensive drug, and the amlodipine/perindopril regimen was superior to atenolol in terms of all-cause mortality, stroke, total cardiovascular events and procedures and new-onset diabetes.

When several variables of the ASCOT-BPLA were analyzed, blood pressure reduction was not the only contributor to the amlodipine/perindopril decrease in cardiovascular events (CitationPoulter et al 2005). Interestingly, although blood pressure was the most important variable associated with the incidence of stroke, differences in HDL cholesterol were more important for coronary events. Furthermore, full adjustment for these variables as well as for bodyweight, and glucose, triglycerides, creatinine and potassium serum levels explained only 50% and 40% of the differences in coronary and stroke events, respectively, leaving the remaining percentages to be potentially explained by other variables not considered in this analysis. These data suggest that blood pressure reduction is not the only mediator in the beneficial effect of antihypertensive drugs. Accordingly, several vasculoprotective mechanisms have been demonstrated for anti-hypertensive drugs, the most important of which have been described for those that modulate the renin-angiotensin system (RAS). The same holds true for statins, which have been claimed to exert a part of their beneficial actions by cholesterol-independent mechanisms (CitationBlanco-Colio et al 2003; CitationRay et al 2005).

The ASCOT-LLA (Lipid Lowering Arm), published in 2003, showed data of further interest (CitationSever et al 2003). Ten thousand three-hundred five patients from the ASCOT-BPLA study with total cholesterol concentrations of 6.5 mmol/L or less were randomized to atorvastatin 10 mg/d or placebo. Treatment with the statin reduced the incidence of non-fatal myocardial infarction or fatal coronary heart disease and that of stroke, cardiovascular and coronary events. Thus, using statins in patients with moderately increased or even normal cholesterol levels, but at risk of cardiovascular events because of accompanying hypertension and other CRF, improved their clinical evolution. Remarkably, in the ASCOT-BPLA, an optimal prevention of cardiovascular events was reached in patients randomized to atorvastatin and the amlodipine/perindopril treatment, with a reduction of 48% in the risk of fatal myocardial infarction and non-fatal coronary heart disease and 44% in the incidence of stroke (http://www.broadshow.com/ascot/press-material.php).

Dyslipidemia and hypertension share common pathways leading to atherothrombosis

Three findings are of special interest in the above-mentioned data. First, a statin, a cholesterol-lowering drug, is beneficial in the treatment of patients who are at risk of cardiovascular events because of the coexistence of several risk factors for atherothrombosis, even when their cholesterol levels are normal or only moderately elevated. Second, blood pressure control and lipid lowering seem not to account for all the reduction achieved by antihypertensive and statin treatments respectively. And, third, the combination of a statin and an effective antihypertensive regimen leads to the best prevention results.

These facts suggest that the pathophysiologic pathways that link hypertension and dyslipidemia to atherothrombosis may share common mechanisms, and this may be similar for other cardiovascular risk factors. This idea is supported by clinical data showing that statins may diminish blood pressure levels (CitationGlorioso et al 1999). However, most evidence supporting this possibility comes from basic research. In this setting, the enhanced activity of the RAS, which plays an important role in hypertension, can activate similar mechanisms to dyslipidemia in endothelial dysfunction, inflammation and thrombosis.

Endothelial dysfunction in the crossroad between hypertension and dyslipidemia

All major atherothrombotic risk factors induce endothelial dysfunction. The key feature in this disorder is a reduced availability of nitric oxide (NO) due to both a decrease in its synthesis and to an enhanced degradation. Hypercholesterolemia plays an important role in this setting, as oxidized LDL diminishes the expression of endothelial NO synthase (eNOS) (CitationLaufs et al 1998). Furthermore, in hypercholesterolemia there is an increase of asymmetric dimethylarginine levels, an eNOS endogenous inhibitor (CitationIto et al 1999). Angiotensin (Ang) II may also downregulate eNOS expression via protein-kinase C (CitationHarrison et al 1995), thus leading to a decrease in NO production. In addition, both hypercholesterolemia and Ang II can participate in NO degradation. Oxidized LDL contributes to oxidative stress, where superoxide anion is generated by endothelial oxidase enzymes. Superoxide reacts with NO yielding peroxynitrite (ONOO-), a compound which, in high amount, works as a strong oxidant and is toxic to proteins (CitationIschiropoulos et al 1995). On the other hand, Ang II is a powerful oxidant agent that increases superoxide anion production through NADH/NADPH in vivo an in vitro via AT1 receptors (CitationRajagopalan et al 1996). Angiotensin II can generate reactive oxygen species (ROS), which activate different intracellular signaling cascades, including mitogen-activated protein kinases (MAPK) and the transcription factor NF-κB (CitationHernández-Presa et al 1997; CitationUshio-Fukai et al 1998). Statins are able to counterbalance the effect of oxidative stress, and decrease the NF-κB activity induced by superoxide anion (CitationOrtego et al 1999).

In the setting of endothelial dysfunction, there is an increase in vascular permeability to LDL, which becomes oxidized in the arterial wall where the macrophages uptake them evolving into foam cells. These processes are promoted by AT1 receptor activation (CitationKeidar et al 1997). In fact, the expression of the oxidized LDL receptor LOX is enhanced through AT1 activation (CitationMorawietz et al 1999). Moreover, the expression of this receptor is induced by LDL in vascular smooth muscle cells, and is enhanced in experimental models of atherosclerosis (CitationNickenig et al 1997; CitationWarnholtz et al 1999). In addition, ACE is present in greater amounts in atherosclerotic plaques (CitationDiet et al 1996). Thus, lipid-lowering drugs are not the unique strategy to lessen these LDL-related biological processes. In agreement with these data, angiotensin receptor blockers (ARBs) have been shown to decrease atheroma formation (CitationWarnholtz et al 1999).

According to all this evidence, multiple studies in the literature have demonstrated that both statins and RAS inhibitors improve the endothelial function in human beings (CitationMancini et al 1996; CitationO’Driscoll et al 1997; CitationTuñón et al 2004; CitationCeriello et al 2005). Furthermore, there is an additive effect of hypertension and dyslipidemia. The infusion of Ang II in patients with hypercholesterolemia increases blood pressure and AT1 expression more than twice as compared with healthy subjects, and these responses are normalized by treatment with statins (CitationNickenig et al 1999). Finally, the combination of a statin and an ARB are superior to each drug alone in reducing the extent of atherosclerosis and the expression of LOX-1 and p38 MAPK in the apo-E knockout mice (CitationChen et al 2006). This fact reinforces the idea of the interplay between the atherothrombotic pathways of the RAS and hypercholesterolemia.

Common pathways to inflammation for Ang II and dyslipidemia

Another important feature in the pathophysiology of atherothrombosis is inflammatory cell recruitment into the vascular wall. This phenomenom is due to the expression of adhesion and chemoattractant molecules by the endothelium, which is regulated, among others, by the transcription factor NF-κB (CitationBarnes et al 1997). This transcription factor plays a key role in the atherothrombotic process, since it also controls the expression of many other proinflammatory and prothrombotic proteins, including that of tissue factor, the trigger of thrombosis in the atheroma plaque. The activation of NF-κB is enhanced, among other stimuli, by ROS and oxLDL, and inhibited by HDL (CitationBarnes et al 1997; CitationXu et al 1999; CitationRobbesyn et al 2003). In this regard, we have shown that statins decrease NF-κB activity in vitro and in a rabbit model of atherosclerosis (CitationBustos et al 1998; CitationOrtego et al 1999). However, we have also demonstrated that Ang II is able to induce NF-κB activity in cultured monocytic and vascular smooth muscle cells (CitationHernández-Presa et al 1997). In this effect, Ang II-induced ROS generation may play an important role, as it was inhibited by pyrrolidinedithiocarbamate (CitationOrtego et al 1999). In fact, ARB treatment diminishes free radical generation and NF-κB binding in mononuclear cells of healthy subjects (Dandona et al 2004).

In addition, Ang II induces leukocyte-endothelial cell interactions and upregulates the expression of several adhesion molecules and chemoattractant cytokines, including MCP-1 (monocyte chemoattractant protein-1), IL-6 (interleukin-6), and IL-8, mainly through AT1 receptors (Hernandez-Presa et al 1997; CitationSchieffer et al 2000; CitationIto et al 2002; CitationRiaz et al 2004). In addition, RAS inhibitors decrease inflammation in human beings and in experimental models of atherosclerosis (CitationHernández-Presa 1997, Citation1998; CitationCipollone et al 2004; CitationFliser et al 2004). For instance, the ARB irbesartan reduces macrophage infiltration, and the expression of the proinflammatory enzyme cyclooxygenase-2 (COX-2) and metalloproteinases in human carotid plaques (CitationCipollone et al 2004). Also, olmesartan has demonstrated recently to diminish plasma levels of C reactive protein, TNF-α, IL-1 and MCP-1 in patients with arterial hypertension and microinflammation (CitationFliser et al 2004).

With regard to statins, there is a huge amount of information showing that they may downregulate the NF-κB pathway, decreasing the expression of adhesion molecules, chemoattractant cytokines, that of the proinflammatory enzyme COX-2 and plasma levels of several inflammatory markers (CitationBustos et al 1998; CitationHernández-Presa et al 1998; CitationOrtego et al 1999; CitationBlanco-Colio et al 2003). In this regard, we have demonstrated that atorvastatin decreases NF-κB activity, MCP-1 expression and macrophage infiltration in human atherosclerotic plaques in only one month of treatment (CitationMartín-Ventura et al 2005). Of interest, the expression of metalloproteinases is enhanced by Ang II in smooth muscle cells and reduced by statins (CitationLuan et al 2003; CitationLuchtefeld et al 2005). Furthermore, statins are able to inhibit the Ang II-induced expression of MCP-1 and IL-8 in vascular smooth muscle cells (CitationOrtego et al 1999; CitationIto et al 2002), confirming the interaction between the inflammatory pathways triggered by dyslipidemia and the RAS. Finally, the combination of atorvastatin and irbesartan reduced C-reactive protein and IL-6 levels more effectively than each of two drugs alone in diabetic patients (CitationCeriello et al 2005).

There are other crosslinks between RAS and statins in inflammation. Vascular permeability is augmented by Ang II via AT1 receptors, while it is decreased by statins (CitationBonetti et al 2002; CitationVictorino et al 2002). Ang II and dyslipidemia share also their effects on fibrosis, the part of the inflammatory process that repairs the damaged tissue, but that in atherosclerosis also results in plaque growth. In this sense, the expression of PDGF (platelet-derived growth factor), TGF-β1 (transforming growth factor-β1) and CTGF (connective tissue growth factor), that mediate the growth-promoting effect of Ang II, is reduced not only by ARBs and ACE inhibitors, but also by statins (CitationGrandaliano et al 1993; CitationWong et al 1997; CitationKim et al 2000; CitationIwanciw et al 2003; CitationRupérez et al 2003). Moreover, these drugs are able to decrease Ang II-induced expression of CTGF (CitationIwanciw et al 2003).

Lipids, RAS and thrombosis

Thrombosis is a critical component of the atherosclerotic disorder, and leads to acute coronary syndromes and ischemic stroke. It begins with platelet adhesion and aggregation, followed by activation of the coagulation cascade. Tissue factor activation is the first step of the cascade coagulation in vascular thrombosis, and this factor is present in the lipid core component of the atherosclerotic plaques (CitationToschi et al 1997). Platelets express AT1 receptors, and ACE inhibitors and ARBs have been demonstrated to inhibit platelet aggregration (CitationJames et al 1988; CitationCrabos et al 1993; CitationSchieffer et al 2004). Also, losartan works as a competitive antagonist of thromboxane A2, a compound derived from COX-1 activity which induces platelet aggregation (CitationCorriu et al 1995). Statins also interfere with these pathways, as they diminish platelet aggregation, thromboxane A2 synthesis and thrombin-induced tissue factor expression in endothelial cells (CitationDavi et al 1992; CitationNotarbartolo et al 1995; CitationEto et al 2002). Moreover, Ang II induces tissue factor expression in human monocytes via the protein kinase C pathway, and ARBs decrease tissue factor activity in hypertensive patients (CitationKoh et al 2004; CitationHe et al 2006). Also, RAS is involved in the regulation of the endogenous fibrinolytic system. Ang II induces the expression of the inhibitor of spontaneous thrombolysis PAI-1 (plasminogen activator inhibitor type 1), and RAS inhibitors decrease PAI-1 plasma levels, which are enhanced following a myocardial infarction (CitationWright et al 1994; CitationKoh et al 2004). Moreover, ACE inhibitors block bradykinin degradation, and this peptide induces the expression of t-PA (tissue plasminogen activator) (CitationVaughan et al 1995). Similarly, statins increase the synthesis of t-PA and decrease PAI-1 (CitationEssig et al 1998; CitationBourcier et al 2000). Very recently, we have observed that intensive treatment with atorvastatin after an acute coronary syndrome enhances the expression of annexin II, a receptor for tissue plasminogen activator and plasminogen, in circulating monocytes (CitationTuñón et al 2007). In conclusion, Ang II and dyslipidemia also act through common mechanisms to promote thrombus formation, which is ultimately responsible for acute ischemic events in atherothrombosis. Combining adequately RAS modulators with statins may reduce the probabilities of developing cardiovascular events by interfering with these actions.

Clinical implications

Several pathways of the essential biological processes in atherothrombosis are shared by dyslipidemia and Ang II, and these mechanisms are targets for RAS modulators and statins. Then, the isolated approach to the treatment of separated risk factors for atherothrombosis seems to be over, since evidence from basic and clinical research clearly indicates that the pathways by which multiple risk factors lead to this disorder are strongly interrelated. In fact, current practice guidelines for the management of hypertension and dyslipidemia take into account the existence of other risk factors to advice the intensity of antihypertensive and cholesterol-lowering therapy. Moreover, polypill combinations of antihypertensive and lipid-lowering drugs are already available in one tablet, such as amlodipine and atorvastatin (CADUET), and others, such as ARB and statins, will be probably coming soon. It follows that the next step for this approach should be the evolution of the traditional hypertension and dyslipidemia Units into cardiovascular risk management departments. These changes would provide the necessary tools to treat our patients in accordance with the current strategies of cardiovascular therapy and prevention.

References

  • BarnesPJKarinMNuclear factor-κB. A pivotal transcription factor in chronic inflammatory diseasesN Engl J Med19973361066719091804
  • Blanco-ColioLMTuñónJMartín-VenturaJLAnti-inflammatory and immunomodulatory effects of statinsKidney Int200363122312472764
  • BonettiPOWilsonSHRodriguez-PorcelMSimvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid loweringJ Am Coll Cardiol2002405465412142124
  • BourcierTLibbyPHMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cellsArterioscler Thromb Vasc Biol2000205566210669656
  • BustosCHernández-PresaMAOrtegoMHMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosisJ Am Coll Cardiol1998322057649857893
  • CerielloAAssaloniRDa RosREffect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patientsCirculation200511125182415867169
  • ChenJLiDSchaeferRCross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis Studies with the combined use of rosuvastatin and candesartanAtherosclerosis200618429530116005008
  • CipolloneFFaziaMIezziABlockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activityCirculation20041091482815037537
  • CorriuCBernardSSchottCEffects of losartan on contractile responses of conductance and resistance arteries from ratsJ Cardiovasc Pharmacol199526688928637181
  • CrabosMBrertschinSBühlerFRIdentification of AT1 receptors on human platelets and decreased angiotensin II binding in hypertensionJ Hypertens Suppl199311S23018158359
  • DahlofBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet200536689590616154016
  • DandonaPKumarVAljadaAAngiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory actionJ Clin Endocrinol Metab200388449650112970329
  • DaviGAvernaMCatalanoIIncreased thromboxane biosynthesis in type IIa hypercholesterolemiaCirculation199285179281572035
  • DietFPrattREBerryGJIncreased accumulation of tissue ACE in human atherosclerotic coronary artery diseaseCirculation1996942756678941100
  • EssigMNguyenGPrieD3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteinsCirc Res199883683909758637
  • EtoMKozaiTCosentinoFStatin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathwaysCirculation20021051756911956113
  • FliserDBuchholzKHallerHAntiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammationCirculation20041101103715313950
  • GloriosoNTroffaCFilighedduFEffect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemiaHypertension1999341281610601131
  • GrandalianoGBiswasPChoudhuryGGSimvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cellsKidney Int19934450388231022
  • HarrisonDGVenemaRCArnalJFThe endothelial cell nitric oxide synthase: is it really constitutively expressed?Agents Actions Suppl199545107177536382
  • HeMHeXXieQAngiotensin II induces the expression of tissue factor and its mechanism in human monocytesThromb Res20061175799015953627
  • Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet200236072212114036
  • Hernández-PresaMBustosCOrtegoMAngiotensin Converting enzyme inhibition prevents arterial NF-kB activation, MCP-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosisCirculation1997951532419118522
  • Hernández-PresaMABustosCOrtegoMThe ACE inhibitor quinapril reduces the arterial expression of NF-κB dependent proinflammatory factors but not of collagen in a rabbit model of atherosclerosisAm J Pathol19981531825379846973
  • Hernández-PresaMAMartín-VenturaJLOrtegoMAtorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cellsAtherosclerosis2002160495811755922
  • IschiropoulosHAl-MehdiABPeroxynitrite-mediated oxidative protein modificationsFEBS Lett1995364279827758583
  • ItoKIkedaUYamamotoKRegulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cellsAtherosclerosis200216551512208470
  • ItoATsaoPSAdimoolamSNovel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolaseCirculation1999993092510377069
  • IwanciwDRehmMPorstMInduction of connective tissue growth factor by angiotensin II: integration of signaling pathwaysArterioscler Thromb Vasc Biol2003231782712947014
  • JamesIMDickensonEJBurgoyneWTreatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregationJ Hum Hypertens198822153070031
  • KannelWBDawberTRKaganAFactors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham StudyAnn Intern Med196155335013751193
  • KeidarSAttiasJAngiotensin II injection into mice increases the uptake of oxidized LDL by their macrophages via a proteoglycan-mediated pathwayBiochem Biophys Res Commun19972396379345270
  • KimSIHanDCLeeHBLovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cellsJ Am Soc Nephrol20001180710616843
  • KohKKChungWJAhnJYAngiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled studyAtherosclerosis20041771556015488878
  • LaufsULa FataVPlutzkyJUpregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitorsCirculation1998971129359537338
  • LuanZChaseAJNewbyACStatins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophagesArterioscler Thromb Vasc Biol2003237697512663370
  • LuchtefeldMGroteKGrothusenCAngiotensin II induces MMP-2 in a p47phox-dependent mannerBiochem Biophys Res Commun2005328183815670768
  • ManciniGBHenryGCMacayaCAngiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) StudyCirculation19969425865 Erratum in: Circulation, 1996;94:14908759064
  • Martín-VenturaJLBlanco-ColioLMGómez-HernándezAIntensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one monthStroke200536179680016020773
  • McGillHGFusterVRossRTopolEMajor risk factors and primary prevention: OverviewAtherosclerosis and coronary artery disease1996PhiladelphiaLippincott-Raven2541
  • MorawietzHRueckschlossUNiemannBAngiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoproteinCirculation199910089990210468518
  • NickenigGBäumerATTemurYStatin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic menCirculation19991002131410571970
  • NickenigGSachinidisAMichaelsenFUpregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cellsCirculation19979547389008466
  • NotarbartoloADaviGAvernaMInhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemiaArterioscler Thromb Vasc Biol199515247517749833
  • O’DriscollGGreenDTaylorRRSimvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 monthCirculation1997951126319054840
  • OrtegoMBustosBHernández-PresaMAAtorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cellsAtherosclerosis1999147253610559511
  • OrtegoMGómez HernándezAVidalCHMG-CoA reductase inhibitors reduce I kappa B kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cellsJ Cardiovasc Pharmacol2005454687515821443
  • PoulterNRWedelHDahlofBRole of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)Lancet20053669071316154017
  • RajagopalanSKurzSMünzelTAngiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations to vasomotor toneJ Clin Invest1996971916238621776
  • RayKKCannonCPThe potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromesJ Am Coll Cardiol20054614253316226165
  • RiazAAWangYSchrammRRole of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colonFASEB J200418881315001561
  • RobbesynFGarciaVAugeNHDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappaB activation in smooth muscle cellsFASEB J200317743512586748
  • RupérezMLorenzoOBlanco-ColioLMConnective tissue growth factor is a mediator of angiotensin II-induced fibrosisCirculation2003108149950512952842
  • SchiefferBBunteCWitteJComparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery diseaseJ Am Coll Cardiol200444362815261932
  • SchiefferBSchiefferEHilfiker-KleinerDExpression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instabilityCirculation20001011372810736279
  • SeverPSDahlofBPoulterNRPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet200336111495812686036
  • ToschiVGalloRLettinoMTissue factor modulates the thrombogenicity of human atherosclerotic plaquesCirculation19979559499024145
  • TuñónJBarderasMGJiménez–NácherJJAtorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndromeJ Am Coll Cardiol200749Suppl A355A
  • TuñónJEgidoJEndothelial dysfunction, inflammation and statins: new evidencesRev Esp Cardiol200457903515469785
  • Ushio-FukaiMAlexanderRWAkersMp38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophyJ Biol Chem19982731502299614110
  • VaughanDERouleauJLPfefferMARole of the fibrinolytic system in preventing myocardial infarctionEur Heart J199516Suppl K3168869133
  • VictorinoGPNewtonCRCurranBEffect of angiotensin II on microvascular permeabilityJ Surg Res2002104778112020123
  • WarnholtzANickenigGSchulzEIncreased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin systemCirculation19999920273310209008
  • WongJRauhoftCDilleyRJAngiotensin-converting enzyme inhibition abolishes medial smooth muscle PDGF-AB biosynthesis and attenuates cell proliferation in injured carotid arteries: relationships to neointima formationCirculation1997961631409315558
  • WrightRAFlapanADAlbertiKGEffects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarctionJ Am Coll Cardiol19942467738006284
  • XuXPMeiselSROngJMOxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophagesCirculation199999993810051290
  • YusufSSleightPPogueJEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med20003421455310639539